News from onclive.comFollowNews from onclive.comYour destination for news from onclive.com. See how onclive.com’s media bias impacts the breaking news stories of today.We’ve aggregated 1,341 of onclive.com’s headlines and news stories over the past 3 months. onclive.com’s media bias is . Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check. onclive.com’s aggregated factuality score is Unknown. Factuality is assigned by combining fact check, credibility, and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.Follow Your destination for news from onclive.com. See how onclive.com’s media bias impacts the breaking news stories of today. We’ve aggregated 1,341 of onclive.com’s headlines and news stories over the past 3 months. onclive.com’s media bias is . Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check. onclive.com’s aggregated factuality score is Unknown. Factuality is assigned by combining fact check, credibility, and reliability ratings from Ad Fontes Media and Media Bias/Fact Check. Information about onclive.comWhere is onclive.com located?onclive.com's WebsiteMedia Bias RatingsDo you diasgree? Edit biasLearn more about Media Bias Ratings.FactualityAverage Factuality Rating: UnknownLearn more about Factuality Ratings.Top onclive.com NewsCancer · MarylandMajor Shifts in Urothelial Cancer Care: Immunotherapy Redefines StandardsCoverage: 2 sources(MedPage Today) -- Recent advances in immunotherapy and combination therapies are revolutionizing the treatment landscape for both metastatic and muscle-invasive urothelial cancer. In this exclusive MedPage Today video, Vadim Koshkin, MD, of the...See the StoryUnited States · United StatesJazz Pharmaceuticals receives FDA approval for biliary tract cancer treatment100% Center coverage: 1 sources(Reuters) -The U.S. Food and Drug Administration approved Jazz Pharmaceuticals’ drug for the treatment of a type of biliary tract cancer, the company said on Wednesday. The drug zanidatamab-hrii, sold under the brand name Ziihera, is approved for use in previously treated adults with metastatic HER2-positive biliary tract cancer. HER2 is a protein that stimulates quick growth of cancer cells. Its presence in solid tumor form includes biliary tra…See the StoryDr Harding on the FDA Approval of Zanidatamab for HER2+ Biliary Tract CancerJames J. Harding, MD, discusses the significance of the FDA approval of zanidatamab for pretreated, unresectable or metastatic HER2+ biliary tract cancer.See the StoryLatest News StoriesTopics Most Covered by onclive.comCancerBreast CancerFDAEuropean UnionMerckCancerBreast CancerFDASources Covering Similar Topicstargetedonc.comcancernetwork.comPharmacy Timesstocktitan.netpipelinereviewtargetedonc.comcancernetwork.comPharmacy TimesSuggest a sourceLooking for a source we don't already have? Suggest one here.You've scrolled to the bottom of the feed, there are no more stories.
